RBC Capital analyst Conor McNamara maintained a Buy rating on Maravai Lifesciences Holdings (MRVI – Research Report) on February 4 and set a ...
In a report released today, Matt Hewitt from Craig-Hallum maintained a Buy rating on Maravai Lifesciences Holdings (MRVI – Research Report).
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Get Free Report) was the recipient of unusually large options trading activity on Wednesday. Stock traders acquired 1,002 put options on the company.
KURT ORESHACK, the General Counsel of $MRVI, sold 25,000 shares of the company on 01-31-2025 for an estimated $125,750. We received data on the trade from a recent ...
TriLink BioTechnologies (TriLink®), a Maravai® LifeSciences company (NASDAQ: MRVI) and global provider of life science ...
TriLink BioTechnologies (TriLink®), a Maravai® LifeSciences company (NASDAQ: MRVI) and global provider of life science ...
Thermo Fisher Scientific Inc. (NYSE:TMO), a leading player in the Life Science Tools & Diagnostics sector, has been navigating a complex market landscape characterized by both challenges and ...
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI), a leading provider of critical products to enable the development of drug therapies, diagnostics, and novel vaccines, has ...
Zacks.com on MSN2d
MCK Stock Before Q3 Earnings: A Smart Buy or Risky Investment?McKesson Corporation MCK is scheduled to report third-quarter fiscal 2025 results on Feb. 5, after market close. The company ...
Prudent Investment Analysis requires observations of the support and resistance levels for Maravai Lifesciences Holdings Inc. (NASDAQ: MRVI) too. These define prudent trading plans. This is a static ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback